TIRZEPATIDE - 5mg
Tirzepatide is a synthetic peptide-based compound designed to mimic the effects of two naturally occurring incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It is primarily recognized in research models for its potential to regulate glucose metabolism, improve insulin sensitivity, and influence energy balance.
A synthetic dual GIP and GLP-1 receptor agonist modeled for laboratory research.
Tirzepatide is a synthetic peptide-based compound designed to mimic the effects of two naturally occurring incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It is primarily recognized in research models for its potential to regulate glucose metabolism, improve insulin sensitivity, and influence energy balance.
By activating both GIP and GLP-1 receptors, Tirzepatide has been shown in laboratory settings to stimulate insulin secretion in a glucose-dependent manner, reduce glucagon release, delay gastric emptying, and promote satiety. Its dual-target mechanism has made it a subject of interest in studies on type 2 diabetes, obesity, and metabolic syndrome.
Titan research and immune system function
Metabolic Regulation:
Studied for its ability to improve insulin sensitivity and glucose control in experimental diabetes models.
Appetite & Weight Management:
Research explores Tirzepatide’s effects on reducing food intake and promoting weight loss via satiety signaling.
Energy Expenditure:
Investigations assess its role in shifting energy metabolism towards increased fat utilization.
Cardiometabolic Health:
Studies examine its impact on blood pressure, lipid levels, and inflammatory biomarkers.
Combination Therapy Potential:
Interest in exploring Tirzepatide alongside other agents for synergistic effects in metabolic disorders.
Titan research and immune system function
Dual Incretin Pathway Modulation:
Unique in simultaneously activating GIP and GLP-1 receptors, offering potentially additive or synergistic effects.
Glucose Homeostasis Studies:
Regulates postprandial glucose spikes and fasting glucose levels in research models.
Appetite & Satiety Signaling:
Modifies hypothalamic pathways to influence hunger and fullness cues.
(1) Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. → SURMOUNT-1 trial showed steady weight loss as early as week 1, with around 3–3.5% loss by week 4 depending on dosage. [New England Journal of Medicine, 387(3), 205–216]
(2) Frias, J. P., et al. (2021). Tirzepatide vs. Semaglutide for type 2 diabetes and weight reduction. → Participants on 15 mg saw more rapid early weight loss than Semaglutide. [New England Journal of Medicine, 385(6), 503–515]
(3) Min, T., et al. (2022). Dual GIP and GLP-1 receptor agonism and energy balance. → Reviews Tirzepatide’s mechanism for synergistic appetite suppression and improved insulin action, contributing to fast weight loss.
The chart demonstrates the weight loss effects of Tirzepatide over a four-week period in human clinical data. During the first week, participants experienced an estimated 0.6% reduction in body weight, representing an early but noticeable response. By the second week, this reduction increased to 1.5%, showing a steady upward trend as treatment continued.
By week four, the estimated body weight reduction reached 3.2%, more than doubling the effect seen at week two. This progressive pattern highlights Tirzepatide’s potential to deliver sustained and incremental weight loss benefits within a relatively short timeframe, aligning with its profile as a multi-incretin therapeutic in obesity and metabolic research.
Form:
Lyophilized Powder
Storage (unreconstituted):
- Store at 2–8 °C (refrigerated), protected from light.
- For long-term storage, keep at –20 °C.
- Avoid repeated freeze–thaw cycles.
Reconstitution:
- Reconstitute with sterile water for injection or 0.9% NaCl immediately prior to use. Use aseptic technique.
Storage (after reconstitution):
- Store at 2–8 °C.
- Use within 7–10 days.
- Discard any unused solution after this period.
- Handle under sterile conditions.
- Do not shake vigorously (may cause peptide denaturation).
- Inspect visually for particulate matter or discoloration before use.
Issued for quality verification of tested material.
Feedback highlighting proven outcomes and reliability.
